The concern of generic competition has long loomed around copyright’s famous drug, Sildenafil, sparking questions about the outlook of connected pharmaceutical stakes. While first periods saw significant returns, the intellectual property expiration has opened the way for discounted substitutes, potentially diminishing earnings and presenting a r